Reducing tetracycline resistance in living cells

Details Reducing tetracycline resistance in living cells Reducing tetracycline resistance in living cells

2008-08-19

2010-06-08

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

3,10-dihydroxy-2-naphthacene carboxamide or derivative doai

Reexamination Certificate

active

07732429

ABSTRACT:
The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such asS. aureusandE. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.

REFERENCES:
patent: 2980584 (1961-04-01), Hammer
patent: 2990331 (1961-06-01), Neumann et al.
patent: 3062717 (1962-11-01), Hammer
patent: 3165531 (1965-01-01), Nelson et al.
patent: 3236736 (1966-02-01), Fitch et al.
patent: 3454697 (1969-07-01), Joyner et al.
patent: 3557280 (1971-01-01), Weber et al.
patent: 3579564 (1971-05-01), Blackwood et al.
patent: 3674859 (1972-07-01), Beutel et al.
patent: 3863009 (1975-01-01), Johnston
patent: 3957980 (1976-05-01), Noseworthy
patent: 4018889 (1977-04-01), Armstrong
patent: 4024272 (1977-05-01), Rogalski et al.
patent: 4126680 (1978-11-01), Armstrong et al.
patent: 4806372 (1989-02-01), Strumskis
patent: 4806529 (1989-02-01), Levy
patent: 5021407 (1991-06-01), Levy
patent: 5064821 (1991-11-01), Levy
patent: 5258372 (1993-11-01), Levy
patent: 5589470 (1996-12-01), Levy
patent: 5811412 (1998-09-01), Levy
patent: 6256365 (2001-07-01), Lai
patent: 6500812 (2002-12-01), Nelson et al.
patent: 6617318 (2003-09-01), Nelson et al.
patent: 6624168 (2003-09-01), Nelson et al.
patent: 6642270 (2003-11-01), Nelson et al.
patent: 6683068 (2004-01-01), Nelson et al.
patent: 6818634 (2004-11-01), Nelson et al.
patent: 6818635 (2004-11-01), Nelson et al.
patent: 6833365 (2004-12-01), Levy et al.
patent: 6841546 (2005-01-01), Draper et al.
patent: 6846939 (2005-01-01), Nelson et al.
patent: 6849615 (2005-02-01), Nelson et al.
patent: 7001918 (2006-02-01), Huss et al.
patent: 7045507 (2006-05-01), Draper et al.
patent: 7056902 (2006-06-01), Nelson et al.
patent: 7067681 (2006-06-01), Nelson et al.
patent: 7094806 (2006-08-01), Nelson et al.
patent: 7202235 (2007-04-01), Levy et al.
patent: 7208482 (2007-04-01), Garcia-Luzon et al.
patent: 7323492 (2008-01-01), Huss et al.
patent: 7326696 (2008-02-01), Nelson et al.
patent: 7361674 (2008-04-01), Nelson et al.
patent: 7414041 (2008-08-01), Levy
patent: 7521437 (2009-04-01), Nelson et al.
patent: 7553828 (2009-06-01), Nelson et al.
patent: 2003/0069721 (2003-04-01), Podlogar
patent: 2004/0138183 (2004-07-01), Nelson et al.
patent: 2004/0176334 (2004-09-01), Nelson et al.
patent: 2004/0214800 (2004-10-01), Levy et al.
patent: 2004/0214801 (2004-10-01), Nelson et al.
patent: 2004/0242548 (2004-12-01), Draper et al.
patent: 2005/0020545 (2005-01-01), Draper et al.
patent: 2005/0038002 (2005-02-01), Nelson et al.
patent: 2005/0070510 (2005-03-01), Draper et al.
patent: 2005/0143352 (2005-06-01), Nelson et al.
patent: 2005/0250744 (2005-11-01), Levy et al.
patent: 2005/0288262 (2005-12-01), Bandarage et al.
patent: 2006/0003971 (2006-01-01), Nelson
patent: 2006/0084634 (2006-04-01), Huss et al.
patent: 2006/0089336 (2006-04-01), Nelson et al.
patent: 2006/0166944 (2006-07-01), Berniac et al.
patent: 2006/0166945 (2006-07-01), Abato et al.
patent: 2006/0166946 (2006-07-01), Nelson et al.
patent: 2006/0194773 (2006-08-01), Levy et al.
patent: 2006/0281717 (2006-12-01), Berniac et al.
patent: 2006/0287283 (2006-12-01), Amoo et al.
patent: 2007/0072834 (2007-03-01), Nelson et al.
patent: 2007/0093455 (2007-04-01), Abato et al.
patent: 2007/0167415 (2007-07-01), Levy et al.
patent: 2007/0270389 (2007-11-01), Garcia-Luzon et al.
patent: 2008/0015169 (2008-01-01), Nelson et al.
patent: 2008/0070873 (2008-03-01), Alekshun et al.
patent: 2008/0118979 (2008-05-01), Draper et al.
patent: 2008/0167273 (2008-07-01), Nelson et al.
patent: 2008/0287401 (2008-11-01), Johnston et al.
patent: 2008/0300424 (2008-12-01), Nelson et al.
patent: 2008/0306032 (2008-12-01), Nelson et al.
patent: 2008/0312193 (2008-12-01), Assefa et al.
patent: 2009/0054379 (2009-02-01), Huss et al.
patent: 2009/0118269 (2009-05-01), Berniac et al.
patent: 2009/0124583 (2009-05-01), Nelson et al.
patent: 2009/0131696 (2009-05-01), Levy
patent: 2009/0156842 (2009-06-01), Seyedi et al.
patent: WO 84/01895 (1984-05-01), None
Curiale et al., “Two complementation groups mediate tetracycline resistance determined by Tn10”,J. Bacteriol., 151(1): 209-215 (1982).
Levy et al.,Biochemical and Biophysical Res. Commun., 56(4):1060-1068 (1974).
McMurry et al., “Two transport systems for tetracycline in sensitiveEscherichia coli: critical role for an initial rapid uptake system insensitive to energy inhibitors”Antimicrob Agents Chemother., 14(2): 201-209 (1978).
McMurry et al., “Active uptake of tetracycline by membrane vesicles from susceptibleEscherichia coli”, Antimicrob Agents Chemother, 20(3): 307-313 (1981).
McMurry et al., “Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants inEscherichia coli”, Proc Natl Acad Sci USA, 77(7): 3974-3977 (1980).
Ball et al., Biochem. Biophys. Res. Comm., 93:74-81 (1980).
Berge et al., “Pharmaceutical Salts”, J. Pharm. Sci., 66(1):1-19 (1977).
Brock et al., “Comparison of the In Vitro Serum Microbiological Activity of a Triple Tetracycline Tablet, 300 mg B.I.D. with Oxytetracycline, 250 mg Q.I.D.” J. Int. Med. Res., 9:360-364 (1981).
Burdett, V., J. Bact. 165:564-569 (1986).
Chopra et al., “The Tetracyclines: Prospects at the Beginning of the 1980's”, J Antimicrob Chemother., 8:5-21 (1981).
Connamacher et al., Chem. Abst. 89:71494n (1978).
Curiale et al., J. Bact. 157:211-217 (1984).
Grassi, et al., “New Trends in Antibiotics”, Research & Therapy, 3-55 (1981).
Korolkovas, A., et al., Essentials of Medicinal Chem., 512-517 (1976).
Kuck et al., Chem Abst. 74:74941g (1971).
Kuck et al., Chem. Abst. 79:74181n (1973).
Lebek et al., Chem. Abst. 82:26560a (1974).
Lehninger, Biochemistry—The Molecular Basis of Cell Structure and Function, 941 (1975).
Leigh et al., Chem. Abst. 81:115200e (1974).
Levy and McMurry, “Plasmid-Determined Tetracycline Resistance Involves New Transport Systems for Tetracycline”, Nature, 275 (5683):90-92 (1978).
Levy, S.B., “The Tetracyclines: Microbial Sensitivity and Resistance”, New Trends in Antibiotics: Research and Therapy, Elsevier/North-Holland Biomedical Press, 27-44 (1981).
Levy, S.B., Journal of Antimicrobial Chemotherapy, 24:1-3 (1989).
Mendez, B., et al., “Heterogeneity of Tetracycline Resistance Determinants,” Plasmid, 3:99-108 (1980).
Samra et al., Chem Abst. 90:198211u (1978).
Sompolinsky et al., Chem. Abst. 79:143198n (1973).

Affiliated with

Also associated with

Rating

Reducing tetracycline resistance in living cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reducing tetracycline resistance in living cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reducing tetracycline resistance in living cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4245271